mTORC2 deficiency in myeloid dendritic cells enhances their allogeneic Th1 and Th17 stimulatory ability after TLR4 Ligation in vitro and in vivo

Journal of Immunology

Volumn 194, Issue 10, 2015, Pages 4767-4776

  Raïch Regué, Dàlia ^a   Rosborough, Brian R ^a   Watson, Alicia R ^a   McGeachy, Mandy J ^a   Turnquist, Heth R ^a   Thomson, Angus W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DECTIN 1; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE C; PROTEIN SERINE THREONINE KINASE; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TLR4 PROTEIN, MOUSE; TOR COMPLEX 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; GENE DISRUPTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2 DEFICIENCY; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL; TH17 CELL; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW CELL; C57BL MOUSE; COCULTURE; DEFICIENCY; DENDRITIC CELL; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ANIMALS; BLOTTING, WESTERN; COCULTURE TECHNIQUES; DENDRITIC CELLS; FLOW CYTOMETRY; IN VITRO TECHNIQUES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; MYELOID CELLS; TH1 CELLS; TH17 CELLS; TOLL-LIKE RECEPTOR 4; TOR SERINE-THREONINE KINASES;

EID: 84942672282     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402551     Document Type: Article

References (42)

1. Yang, Q., and K. L. Guan. 2007. Expanding mTOR signaling. Cell Res. 17: 666-681.
2. Thomson, A. W., H. R. Turnquist, and G. Raimondi. 2009. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9: 324-337.
3. Powell, J. D., and G. M. Delgoffe. 2010. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 33: 301-311.
4. Wullschleger, S., R. Loewith, and M. N. Hall. 2006. TOR signaling in growth and metabolism. Cell 124: 471-484.
5. Sarbassov, D. D., S. M. Ali, D. H. Kim, D. A. Guertin, R. R. Latek, H. Erdjument-Bromage, P. Tempst, and D. M. Sabatini. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptorindependent pathway that regulates the cytoskeleton. Curr. Biol. 14: 1296-1302.
6. Guertin, D. A., and D. M. Sabatini. 2009. The pharmacology of mTOR inhibition. Sci. Signal. 2: pe24.
7. Laplante, M., and D. M. Sabatini. 2012. mTOR signaling in growth control and disease. Cell 149: 274-293.
8. Yang, Q., K. Inoki, T. Ikenoue, and K. L. Guan. 2006. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 20: 2820-2832.
9. Jacinto, E., R. Loewith, A. Schmidt, S. Lin, M. A. Rüuegg, A. Hall, and M. N. Hall. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6: 1122-1128.
10. Thoreen, C. C., S. A. Kang, J. W. Chang, Q. Liu, J. Zhang, Y. Gao, L. J. Reichling, T. Sim, D. M. Sabatini, and N. S. Gray. 2009. An ATP competitive mammalian target of rapamycin inhibitor reveals rapamycinresistant functions of mTORC1. J. Biol. Chem. 284: 8023-8032.
11. Rosborough, B. R., D. Raïch-Regué, B. M. Matta, K. Lee, B. Gan, R. A. De Pinho, H. Hackstein, M. Boothby, H. R. Turnquist, and A. W. Thomson. 2013. Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction. Blood 121: 3619-3630.
12. Sun, S. Y. 2013. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett. 340: 1-8.
13. Rosborough, B. R., D. Raïch-Regué, Q. Liu, R. Venkataramanan, H. R. Turnquist, and A. W. Thomson. 2014. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am. J. Transplant. 14: 2173-2180.
14. Delgoffe, G. M., K. N. Pollizzi, A. T. Waickman, E. Heikamp, D. J. Meyers, M. R. Horton, B. Xiao, P. F. Worley, and J. D. Powell. 2011. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12: 295-303.
15. Kurebayashi, Y., S. Nagai, A. Ikejiri, M. Ohtani, K. Ichiyama, Y. Baba, T. Yamada, S. Egami, T. Hoshii, A. Hirao, et al. 2012. PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORg. Cell Reports 1: 360-373.
16. Lee, K., P. Gudapati, S. Dragovic, C. Spencer, S. Joyce, N. Killeen, M. A. Magnuson, and M. Boothby. 2010. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 32: 743-753.
17. Zeng, H., K. Yang, C. Cloer, G. Neale, P. Vogel, and H. Chi. 2013. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature 499: 485-490.
18. Delgoffe, G. M., T. P. Kole, Y. Zheng, P. E. Zarek, K. L. Matthews, B. Xiao, P. F. Worley, S. C. Kozma, and J. D. Powell. 2009. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30: 832-844.
19. Araki, K., A. P. Turner, V. O. Shaffer, S. Gangappa, S. A. Keller, M. F. Bachmann, C. P. Larsen, and R. Ahmed. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature 460: 108-112.
20. Lee, K., L. Heffington, J. Jellusova, K. T. Nam, A. Raybuck, S. H. Cho, J. W. Thomas, R. C. Rickert, and M. Boothby. 2013. Requirement for Rictor in homeostasis and function of mature B lymphoid cells. Blood 122: 2369-2379.
21. Hackstein, H., T. Taner, A. F. Zahorchak, A. E. Morelli, A. J. Logar, A. Gessner, and A. W. Thomson. 2003. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 101: 4457-4463.
22. Hackstein, H., T. Taner, A. J. Logar, and A. W. Thomson. 2002. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 100: 1084-1087.
23. Monti, P., A. Mercalli, B. E. Leone, D. C. Valerio, P. Allavena, and L. Piemonti. 2003. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 75: 137-145.
24. Woltman, A. M., J. W. de Fijter, S. W. Kamerling, S. W. van Der Kooij, L. C. Paul, M. R. Daha, and C. van Kooten. 2001. Rapamycin induces apoptosis in monocyte-and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 98: 174-180.
25. + T regulatory cells and promote organ transplant tolerance. J. Immunol. 178: 7018-7031.
26. Weichhart, T., G. Costantino, M. Poglitsch, M. Rosner, M. Zeyda, K. M. Stuhlmeier, T. Kolbe, T. M. Stulnig, W. H. Hörl, M. Hengstschläger, et al. 2008. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29: 565-577.
27. Turnquist, H. R., J. Cardinal, C. Macedo, B. R. Rosborough, T. L. Sumpter, D. A. Geller, D. Metes, and A. W. Thomson. 2010. mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS. Blood 115: 4758-4769.
28. Macedo, C., H. R. Turnquist, M. Castillo-Rama, A. F. Zahorchak, R. Shapiro, A. W. Thomson, and D. Metes. 2013. Rapamycin augments human DC IL-12p70 and IL-27 secretion to promote allogeneic Type 1 polarization modulated by NK cells. Am. J. Transplant. 13: 2322-2333.
29. Ohtani, M., T. Hoshii, H. Fujii, S. Koyasu, A. Hirao, and S. Matsuda. 2012. Cutting edge: mTORC1 in intestinal CD11c+ CD11b+ dendritic cells regulates intestinal homeostasis by promoting IL-10 production. J. Immunol. 188: 4736-4740.
30. Brown, J., H. Wang, J. Suttles, D. T. Graves, and M. Martin. 2011. Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1. J. Biol. Chem. 286: 44295-44305.
31. Morelli, A. E., A. F. Zahorchak, A. T. Larregina, B. L. Colvin, A. J. Logar, T. Takayama, L. D. Falo, and A. W. Thomson. 2001. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 98: 1512-1523.
32. Latchman, Y. E., S. C. Liang, Y. Wu, T. Chernova, R. A. Sobel, M. Klemm, V. K. Kuchroo, G. J. Freeman, and A. H. Sharpe. 2004. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci. USA 101: 10691-10696.
33. Martin, M., K. Rehani, R. S. Jope, and S. M. Michalek. 2005. Toll-like receptor mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6: 777-784.
34. Androulidaki, A., D. Iliopoulos, A. Arranz, C. Doxaki, S. Schworer, V. Zacharioudaki, A. N. Margioris, P. N. Tsichlis, and C. Tsatsanis. 2009. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 31: 220-231.
35. McGeachy, M. J., Y. Chen, C. M. Tato, A. Laurence, B. Joyce-Shaikh, W. M. Blumenschein, T. K. McClanahan, J. J. O'Shea, and D. J. Cua. 2009. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol. 10: 314-324.
36. Gopal, R., Y. Lin, N. Obermajer, S. Slight, N. Nuthalapati, M. Ahmed, P. Kalinski, and S. A. Khader. 2012. IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur. J. Immunol. 42: 364-373.
37. Harrington, L. E., P. R. Mangan, and C. T. Weaver. 2006. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr. Opin. Immunol. 18: 349-356.
38. Lee, Y., A. Awasthi, N. Yosef, F. J. Quintana, S. Xiao, A. Peters, C. Wu, M. Kleinewietfeld, S. Kunder, D. A. Hafler, et al. 2012. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 13: 991-999.
39. Lin, Y., S. Ritchea, A. Logar, S. Slight, M. Messmer, J. Rangel-Moreno, L. Guglani, J. F. Alcorn, H. Strawbridge, S. M. Park, et al. 2009. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31: 799-810.
40. Palma, C., G. Schiavoni, L. Abalsamo, F. Mattei, G. Piccaro, M. Sanchez, C. Fernandez, M. Singh, and L. Gabriele. 2013. Mycobacterium tuberculosis PstS1 amplifies IFN-g and induces IL-17/IL-22 responses by unrelated memory CD4+ T cells via dendritic cell activation. Eur. J. Immunol. 43: 2386-2397.
41. Brown, J., H. Wang, G. N. Hajishengallis, and M. Martin. 2011. TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J. Dent. Res. 90: 417-427.
42. LeibundGut-Landmann, S., O. Gross, M. J. Robinson, F. Osorio, E. C. Slack, S. V. Tsoni, E. Schweighoffer, V. Tybulewicz, G. D. Brown, J. Ruland, and C. Reise Sousa. 2007. Syk-and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol. 8: 630-638.